Publications
19.11.2020
ISPO 2020 Developing a sustainable biosimilar

To facilitate biosimilar uptake, several mechanisms aimed at reducing the acquisition cost of biosim...

Read more
Publications
19.11.2020
COVID-19 impact on HTA bodies

HTA bodies and companies within the pharmaceutical industry have been forced to react to unprecedent...

Read more
Articles
23.10.2020
Sustainable biosimilar marketplaces

To facilitate biosimilar uptake, several mechanisms encouraging biosimilar uptake have been implemen...

Read more
Articles
12.10.2020
What impact has COVID-19 had on HTA bodies

A survey of employees within pricing and market access n pharma and biotech companies.

Read more
News
07.10.2020
Revisiting the influence of ICER in the US

ICER’s Health Technology Assessments review process is an assessment undertaken by one of three ap...

Read more
Articles
22.09.2020
Update and validate legal price certificates

Remap Consulting are ideally placed to support the completion of price certificates ready for legali...

Read more
Articles
17.09.2020
The value of a Global Value Dossier

GVD is a core document, which may be considered the “heart” of the pharmaceutical product’s pa...

Read more
Articles
29.07.2020
Real world data included in NICE

How has the data available within NCRAS been utilized within the CDF overseen by NICE, in partnershi...

Read more
Articles
23.06.2020
COVID-19 impact on pricing and market access

Without a doubt, the impact of COVID-19 will influence all sectors, including the future of market a...

Read more
Articles
20.05.2020
International Reference Pricing

IRP is a pricing mechanism where the price of a drug in one country is set or adjusted in relation t...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.